Published in Br J Cancer on June 26, 2012
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 4.11
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst (2003) 3.20
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat (2005) 2.75
Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol (2007) 2.71
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res (2005) 2.48
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol (2008) 2.34
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst (2007) 1.97
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci (2008) 1.95
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol (2008) 1.92
Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat (2007) 1.68
Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol (2006) 1.47
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat (2009) 1.20
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer (2009) 1.07
CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep (2010) 0.93
Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol (2006) 0.91
Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat (2010) 0.81
A Wilcoxon-type test for trend. Stat Med (1985) 13.22
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet (1993) 7.46
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet (2005) 7.25
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Quality and the use of time in general practice: widening the discussion. BMJ (1989) 5.59
Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer (1996) 5.24
Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med (1992) 5.18
Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet (2002) 5.04
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Progressive potential of mild cervical atypia: prospective cytological, colposcopic, and virological study. Lancet (1986) 4.55
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer (2003) 4.14
The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology (1986) 3.70
An in vitro method for assessing the plaque forming ability of oral bacteria. Arch Oral Biol (1967) 3.11
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10
Mild cervical dyskaryosis: safety of cytological surveillance. Lancet (1992) 3.09
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer (1984) 2.89
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients. J Bone Joint Surg Am (2006) 2.71
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol (1992) 2.67
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum (2006) 2.57
Familial breast cancer. BMJ (1994) 2.54
Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol (2012) 2.45
Uptake of screening and prevention in women at very high risk of breast cancer. Lancet (2001) 2.45
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol (1997) 2.39
Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep (1987) 2.37
Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg (1984) 2.36
Effect of smoking cessation on cervical lesion size. Lancet (1996) 2.35
Perception of risk in women with a family history of breast cancer. Br J Cancer (1993) 2.32
Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer (1996) 2.30
The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology (1995) 2.27
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet (2003) 2.24
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Accelerated decline in cervical cancer mortality in England and Wales. Lancet (1995) 1.95
Psychosexual trauma of an abnormal cervical smear. Br J Obstet Gynaecol (1988) 1.90
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat (2001) 1.88
The Sexual Activity Questionnaire: a measure of women's sexual functioning. Qual Life Res (1996) 1.85
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat (1999) 1.84
Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer (1991) 1.83
A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen (2004) 1.81
Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer (2007) 1.80
Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab (1997) 1.79
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer (2009) 1.77
The use of cervicography in a primary screening service. Br J Obstet Gynaecol (1991) 1.76
Light chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myeloma: Medical Research Council's Working Party for Leukaemia in Adults and the Oxford Lymphoma Group. Int J Cancer (1979) 1.75
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol (2003) 1.75
The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer (1994) 1.75
Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer (1996) 1.71
Final 12-year follow-up of surgery versus surveillance in the UK Small Aneurysm Trial. Br J Surg (2007) 1.70
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 1.70
Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet (1983) 1.69
Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut (1998) 1.68
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer (1996) 1.67
Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet (1988) 1.66
The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer (1989) 1.65
Odontomyces viscosus, gen. nov., spec. nov., a filamentous microorganism isolated from periodontal plaque in hamsters. Sabouraudia (1965) 1.61
The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer (1984) 1.61
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) (2010) 1.61
Psychosocial influences on older adults' interest in participating in bowel cancer screening. Prev Med (2000) 1.59
Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J Natl Cancer Inst (1997) 1.58
Radiation-induced myelomatosis. N Engl J Med (1981) 1.58
Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol (2007) 1.57
Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet (1984) 1.56
Practice budgets: lifting the veil of ignorance. J R Coll Gen Pract (1989) 1.56
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol (2007) 1.54
Tamoxifen and contralateral breast cancer. Lancet (1985) 1.53
Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia (1998) 1.52
A filamentous microorganism isolated from periodontal plaque in hamsters. 1. Isolation, morphology and general cultural characteristics. Sabouraudia (1963) 1.52
Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol (2001) 1.49
Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol (1996) 1.49
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol (2011) 1.49
Can hair be used to screen for breast cancer? J Med Genet (2000) 1.49
A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int J Cancer (1981) 1.46
A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther (2000) 1.45
Five cases of coexistent primary ocular and cutaneous melanoma. Arch Dermatol (1993) 1.45
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy (2012) 1.44
Neuropathic joints. Semin Arthritis Rheum (1972) 1.44
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol (1996) 1.44
Screening by mammography, women with a family history of breast cancer. Eur J Cancer (1998) 1.44
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening. J Med Screen (2001) 1.43